Tenofovir amibufenamide

• CAT Number: I037119
• CAS Number: 1571076-26-0
• Molecular Formula: C22H31N6O5P
• Molecular Weight: 490.50
• Purity: 98%
• Synonyms: Tenofovir amibufenamide
• Target: HBV
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]-2-methylpropanoate
• InChI: InChI=1S/C22H31N6O5P/c1-15(2)32-21(29)22(4,5)27-34(30,33-17-9-7-6-8-10-17)14-31-16(3)11-28-13-26-18-19(23)24-12-25-20(18)28/h6-10,12-13,15-16H,11,14H2,1-5H3,(H,27,30)(H2,23,24,25)/t16-,34-/m1/s1
• InChIKey: ORHSFGJQGPUCRR-JTJFVBHCSA-N
• SMILES: C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@](=O)(NC(C)(C)C(=O)OC(C)C)OC3=CC=CC=C3

Tenofovir Amibufenamide（Cat No.:I037119）is a prodrug of tenofovir designed for improved bioavailability and enhanced pharmacokinetic properties. It is primarily used in the treatment of chronic viral infections, such as HIV and hepatitis B, through its conversion to the active form of tenofovir within the body. By inhibiting the reverse transcriptase enzyme, Tenofovir Amibufenamide prevents viral replication, thereby reducing the viral load. Its optimized formulation offers a more efficient delivery of tenofovir, contributing to better therapeutic outcomes with reduced side effects compared to conventional tenofovir formulations.